Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy

  • Alessandro Biffi
  • Jonathan Rosand


Genetic variation appears to play a substantial role in sporadic intracerebral hemorrhage. In addition to offering the promise of desperately needed preventative treatments, identification of the culprit variants may prove useful in screening individuals for long-term anticoagulation.


Intracerebral Hemorrhage Amyloid Precursor Protein Cerebral Amyloid Angiopathy Cerebral Small Vessel Disease Autosomal Dominant Inheritance Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke. 1983;14(6):924–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006;16(1):30–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33:1190–6.PubMedCrossRefGoogle Scholar
  7. 7.
    van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Morgenstern LB, Hemphill 3rd JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES, American Heart Association Stroke Council and Council on Cardiovascular Nursing, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.PubMedCrossRefGoogle Scholar
  9. 9.
    Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, PROGRESS Collaborative Group, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010;41:394–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745–52.PubMedGoogle Scholar
  11. 11.
    Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161:2125–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093–100.PubMedCrossRefGoogle Scholar
  17. 17.
    Partington SL, Abid S, Teo K, Oczkowski W, O’Donnell MJ. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res. 2007;120:663–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:235–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Rost NS, Greenberg SM, Rosand J. The genetic architecture of intracerebral hemorrhage. Stroke. 2008;39:2166–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet. 2011;88:294–305.PubMedCrossRefGoogle Scholar
  21. 21.
    Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42:565–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Alberts MJ, McCarron MO, Hoffmann KL, Graffagnino C. Familial clustering of intracerebral hemorrhage: a prospective study in North Carolina. Neuroepidemiology. 2002;21:18–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Sundquist K, Li X, Hemminki K. Familial risk of ischemic and hemorrhagic stroke: a large-scale study of the Swedish population. Stroke. 2006;37:1668–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109:813–36.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenberg SM, Vonsattel JPG. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997;28:1418–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169–75.CrossRefGoogle Scholar
  27. 27.
    Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol. 2006;16:55–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, et al. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis. 2003;14:619–23.PubMedCrossRefGoogle Scholar
  29. 29.
    De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis. 1998;5:281–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA. 2000;97:9712–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer’s disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem. 1994;269:17741–8.PubMedGoogle Scholar
  32. 32.
    Stenh C, Nilsberth C, Hammarback J, Engvall B, Naslund J, Lannfelt L. The Arctic mutation interferes with processing of the amyloid precursor protein. Neuroreport. 2002;13:1857–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem. 2001;276:32860–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Von Sattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson Jr EP. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637–49.CrossRefGoogle Scholar
  35. 35.
    Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Sudlow C, Martínez González NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke. 2006;37:364–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Peck G, Smeeth L, Whittaker J, Casas JP, Hingorani A, Sharma P. The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults. PLoS One. 2008;3:e3691.PubMedCrossRefGoogle Scholar
  38. 38.
    Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Garcia C, Pinho e Melo T, Rocha L, Lechner MC. Cerebral hemorrhage and apoE. J Neurol. 1999;246:830–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Seifert T, Lechner A, Flooh E, Schmidt H, Schmidt R, Fazekas F. Lack of association of lobar intracerebral hemorrhage with apolipoprotein E genotype in an unselected population. Cerebrovasc Dis. 2006;21:266–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H, International Stroke Genetics Consortium, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68(6):934–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Biffi A, Kissela B, Ayres AM, Sonni A, Gilson AJ, Schwab K, on behalf of the International Stroke Genetics Consortium, et al. APOE genotype predicts hematoma volume and expansion in intracerebral hemorrhage. Stroke. 2011;42:e102.CrossRefGoogle Scholar
  44. 44.
    McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci. 2000;903:176–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology. 1998;50:961–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Biffi A, Plourde A, Shen Y, Onofrio R, Smith EE, Frosch M, et al. Screening for familial APP mutations in sporadic cerebral amyloid angiopathy. PLoS One. 2010;5:e13949.PubMedCrossRefGoogle Scholar
  47. 47.
    Volonghi I, Pezzini A, Del Zotto E, Giossi A, Costa P, Ferrari D, et al. Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 stroke syndrome. Curr Med Chem. 2010;17:1317–24.PubMedCrossRefGoogle Scholar
  48. 48.
    Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, et al. Role of col4a1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354:1489–96.PubMedCrossRefGoogle Scholar
  49. 49.
    Gusella JF, MacDonald ME. Expanding the notion of disease in Huntington’s disease. Biol Psychiatry. 2007;62:1340.PubMedCrossRefGoogle Scholar
  50. 50.
    Lotery A, Trump D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet. 2007;122:219–36.PubMedCrossRefGoogle Scholar
  51. 51.
    Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59–77.PubMedCrossRefGoogle Scholar
  52. 52.
    Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM, et al. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help? Stroke. 2008;39:3308–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of Neurology and Center for Human Genetic ResearchMassachusetts General HospitalBostonUSA
  2. 2.Division of Neurocritical Care and Emergency Neurology, Department of NeurologyMassachusetts General Hospital (MGH)BostonUSA
  3. 3.MGH Neuroscience Intensive Care Unit, Department of NeurologyMassachusetts General Hospital (MGH)BostonUSA
  4. 4.MGH Center for Human Genetic ResearchMassachusetts General Hospital (MGH)BostonUSA
  5. 5.Program in Medical and Population GeneticsBroad Institute of Harvard and MITCambridgeUSA

Personalised recommendations